Vitamin D and mortality : meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States by Schottker, Ben et al.
Vitamin D and mortality: meta-analysis of individual
participant data from a large consortium of cohort
studies from Europe and the United States
OPEN ACCESS
Ben Schöttker postdoctoral scientist 1, Rolf Jorde professor 2 3, Anne Peasey postdoctoral scientist 4,
Barbara Thorand senior researcher in epidemiology5, Eugène H J M Jansen postdoctoral scientist6,
Lisette de Groot professor of nutrition and ageing7, Martinette Streppel postdoctoral scientist 7, Julian
Gardiner research associate 4, José Manuèl Ordóñez-Mena PhD candidate 1 8, Laura Perna
postdoctoral scientist 1, Tom Wilsgaard professor 9, Wolfgang Rathmann senior researcher in
epidemiology 10, Edith Feskens professor 7, Ellen Kampman professor 7, Galatios Siganos research
associate 9, Inger Njølstad professor 9, Ellisiv Bøgeberg Mathiesen professor 11, Růžena Kubínová
senior researcher 12, Andrzej Pająk professor 13, Roman Topor-Madry senior researcher 13, Abdonas
Tamosiunas professor 14, Maria Hughes postdoctoral scientist 15, Frank Kee professor 15, Martin
Bobak professor 4, Antonia Trichopoulou professor 16 17, Paolo Boffetta professor 16 18, Hermann
Brenner professor 1, on behalf of the Consortium on Health and Ageing: Network of Cohorts in
Europe and the United States (CHANCES)
1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany;
2Tromsø Endocrine Research Group, Department of Clinical Medicine, University of Tromsø (UiT) the Arctic University of Norway, 9037 Tromsø,
Norway; 3Division of Internal Medicine, University Hospital of North Norway, 9038 Tromsø, Norway; 4Department Epidemiology and Public Health,
University College London, London WC1E 6BT, UK; 5Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for
Environmental Health, Neuherberg, Germany; 6Laboratory for Health Protection Research, National Institute for Public Health and the Environment,
3720 BA Bilthoven, Netherlands; 7Division of Human Nutrition, Wageningen University, 6700 EVWageningen, Netherlands; 8Network Aging Research
(NAR), University of Heidelberg, Heidelberg, Germany; 9Epidemiology of Chronic Diseases Research Group, Department of community medicine,
UiT the Arctic University of Norway, 9037 Tromsø, Norway; 10German Diabetes Center, Institute for Biometrics and Epidemiology, Leibniz Center
for Diabetes Research at Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; 11Brain and Circulation Research Group, Department
of clinical medicine, UiT the Arctic University of Norway, 9037 Tromsø, Norway; 12National Institute of Public Health, Prague, Czech Republic;
13Jagiellonian University Medical College, Faculty of Health Sciences, Krakow, Poland; 14Institute of Cardiology of Lithuanian University of Health
Sciences, Kaunas, Lithuania; 15UKCRC Centre of Excellence for Public Health, Queens University Belfast, Northern Ireland, UK; 16Hellenic Health
Foundation, Kaisareias 13 & Alexandroupoleos, Athens 11527, Greece; 17University of Athens, Medical School, Department of Hygiene, Epidemiology
and Medical Statistics, Mikras Asias 75 st, Athens 11527, Greece; 18Institute for Translational Epidemiology and Tisch Cancer Institute, Icahn School
of Medicine at Mount Sinai, New York, NY, USA
Abstract
Objective To investigate the association between serum
25-hydroxyvitamin D concentrations (25(OH)D) and mortality in a large
consortium of cohort studies paying particular attention to potential age,
sex, season, and country differences.
DesignMeta-analysis of individual participant data of eight prospective
cohort studies from Europe and the US.
Setting General population.
Participants 26 018 men and women aged 50-79 years
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Main outcome measures All-cause, cardiovascular, and cancer
mortality.
Results 25(OH)D concentrations varied strongly by season (higher in
summer), country (higher in US and northern Europe) and sex (higher
in men), but no consistent trend with age was observed. During follow-up,
6695 study participants died, among whom 2624 died of cardiovascular
diseases and 2227 died of cancer. For each cohort and analysis,
25(OH)D quintiles were defined with cohort and subgroup specific cut-off
values. Comparing bottom versus top quintiles resulted in a pooled risk
ratio of 1.57 (95% CI 1.36 to 1.81) for all-cause mortality. Risk ratios for
cardiovascular mortality were similar in magnitude to that for all-cause
mortality in subjects both with and without a history of cardiovascular
disease at baseline. With respect to cancer mortality, an association
was only observed among subjects with a history of cancer (risk ratio,
1.70 (1.00 to 2.88)). Analyses using all quintiles suggest curvilinear,
inverse, dose-response curves for the aforementioned relationships. No
strong age, sex, season, or country specific differences were detected.
Heterogeneity was low in most meta-analyses.
Conclusions Despite levels of 25(OH)D strongly varying with country,
sex, and season, the association between 25(OH)D level and all-cause
and cause-specific mortality was remarkably consistent. Results from a
long term randomised controlled trial addressing longevity are being
awaited before vitamin D supplementation can be recommended in most
individuals with low 25(OH)D levels.
Introduction
Although vitamin D is obtained from diet and dietary
supplements, the main source of vitamin D is its production in
skin under the influence of solar ultraviolet B radiation. The
most commonly measured vitamin D metabolite is serum
25-hydroxyvitamin D (25(OH)D) because of its greater half life
(~3 weeks) and up to 1000-fold higher serum levels compared
with the physiologically active metabolite
1,25-dihydroxyvitamin D (half life of a few hours).1 As
ultraviolet B exposure varies with the latitude of regions and
during the year, somean 25(OH)D concentrations of populations
also vary accordingly.2 3 Furthermore, women are generally
more prone to low 25(OH)D concentrations than men (possibly
because of a positive correlation of 25(OH)D with testosterone
levels),4 and vitamin D deficiency is especially common among
elderly people, who often have less sun exposure (because of
reduced outdoor activity) and limited capacity of the skin to
produce vitamin D metabolites.5 However, it is unclear if and
to what extent these influences on production and maintenance
of sufficient vitamin D metabolite concentrations affect the
prognostic association of low 25(OH)D concentrations with
mortality.
The objective of this meta-analysis of a consortium of eight
prospective cohort studies from different European countries
and the United States was to investigate the prognostic
association of 25(OH)D measurements with all-cause,
cardiovascular, and cancer mortality, paying particular attention
to potential differences between countries, sexes, age groups,
and seasons of blood draw.
Methods
This manuscript was written in adherence to the Strengthening
The Reporting of Observational Studies in Epidemiology
(STROBE) and the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) statements.6 7
Study design and study population
This investigation is a meta-analysis of individual participant
data of seven population based cohorts with measured 25(OH)D
of the Consortium on Health and Ageing: Network of Cohorts
in Europe and the United States (CHANCES, www.chancesfp7.
eu) together with the third US National Health And Nutrition
Examination Survey (NHANES III). The cohorts of the
CHANCES consortium were chosen because all variables
needed for this project were harmonised according to pre-defined
rules. The harmonisation rules were discussed among the
CHANCES partners until a consensus was reached. The
NHANES surveywas added to include a North American cohort
and because it has an open access policy that enabled data access
with subsequent conversion according to the CHANCES data
harmonisation rules. The cohorts cover 16 European countries
and the United States. The cohorts’ key characteristics are
summarised in table 1⇓, and the study designs are described in
the supplemental data and previous publications.2 8-12 All
CHANCES cohorts and the NHANES are conducted in
accordance with the declaration of Helsinki, and written
informed consent was obtained from all study participants.
Inclusion and exclusion criteria
To make cohorts more comparable, analyses were restricted to
study participants aged 50-79 years. Current smokers were
excluded from the Tromsø study because the 25(OH)D assay
used resulted in smokers having 15-20% higher 25(OH)D
concentrations than non-smokers which was not reproducible
with other assays.9 In addition, study participants with missing
25(OH)D measurement, missing values for covariates used in
themainmodel, or participants lost to follow-up due to unknown
reasons were excluded. The derivation of the final number of
included study participants is shown for each cohort in table
1⇓.
Mortality ascertainment
All cohorts ascertained deaths by region, state, or country wide
registries with a coverage of ≥98.5% and obtained information
about the underlying cause of death for at least 97.6% of the
deceased. The mean follow-up time ranged from 4.2 to 15.9
years (table 1⇓). All deaths coded with ICD-10 codes I00-I99
were considered cardiovascular deaths, and cancer deaths were
defined by the ICD-10 codes C00-C97.
Measurement of 25(OH)D
Measurement of 25(OH)D was conducted in the full cohorts of
ESTHER, Tromsø, andNHANES III, whereas in SENECA and
MONICA/KORA random subsamples were measured, and in
the three HAPIEE cohorts 25(OH)D was measured in a nested
case-control design (including study participants who died from
any cause as cases). Details of the sampling procedures, the
design of the nested case-control study, and the manufacturers
of the 25(OH)D assays are given in table 1⇓, and further details
have been described previously.2 8 9 11 13 14
Covariate assessment
Sociodemographic, lifestyle, anthropometric, and disease history
data were assessed by self administered questionnaires or in
interviews. In addition to self reported information, some studies
measured weight and height and validated the history of
common chronic diseases by consulting medical records or
registries (such as cancer registries) (supplementary table 1). If
measured anthropometric data or validated diagnoses were
available, these were used in the analysis, and self reported
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information was used only to fill missing information. Prevalent
cardiovascular disease was defined as a history of myocardial
infarction or stroke.
Statistical analyses
This meta-analysis of individual participant data followed a two
step approach by analysing the cohorts individually first and
conducting meta-analyses of the obtained effect estimates
thereafter.
Differences in 25(OH)D concentrations according to baseline
characteristics were assessed with the Wilcoxon rank-sum test.
The longitudinal analyses with mortality outcomes were
conducted using 25(OH)D quintiles because there is still no
consensus about cut off values for 25(OH)D risk categories8 15
and the applied 25(OH)D assays in the cohorts were not
commonly standardised. The cut off values for 25(OH)D
quintiles were allowed to vary by cohort and by analysed
subgroup to ensure that there was always 20% of the analysed
study population in each quintile (see supplementary table 2 for
applied cut off values).
Cox proportional hazards or logistic regression models (the
latter for case-control studies nested in the HAPIEE cohorts)
were used to estimate hazard ratios or odds ratios, respectively,
with 95% confidence intervals for comparison of increasing
25(OH)D quintiles compared with the highest quintile. When
the risk is low, logistic and Cox regression usually produce
similar results and the odds ratio can be regarded as an
approximation of the more accurate hazard ratio that also takes
time to the event into account. We use the term “risk ratios” for
both the effect estimates. Analyses for cardiovascular and cancer
mortality were stratified by presence or absence of a history of
the disease. For sensitivity analyses of all-cause mortality, data
were restricted to subjects without a history of cardiovascular
disease or cancer, respectively. For analyses on cause-specific
mortality, competing risks analysis was employed to correct for
the competing risk of death by other causes.Weights for subjects
who died of competing causes of death were determined
according to an extension of the Fine and Gray method.16
For all outcomes, three models were applied with adjustment
for an increasing number of established risk factors for all-cause
mortality and determinants of serum 25(OH)D concentrations.
In model 1, adjustment was made for age, sex, and season of
blood draw. Model 2 was the fully adjusted model with
additional adjustment for education, bodymass index, smoking,
and physical activity. Model 3 additionally included diseases
that could potentially be intermediates in the association of
25(OH)D and mortality (that is, a history of diabetes,
hypertension, cardiovascular disease, and cancer). Model 2
results were considered the main results. Age was modelled
linearly and the other variables categorically with dummy
variables using the categories shown in table 2⇓. In addition,
the following adjustments for cohort-specific characteristics
were made in all three models: survey for MONICA/KORA,
latitude of study centre for SENECA, and region (west,
mid-west, north-east, south) as well as ethnicity (non-Hispanic
white, non-Hispanic black, Mexican-American, other) for the
NHANES III. Proportions of non-white study participants in
the European studies were negligible.
For all meta-analyses, Mantel-Haenszel weighting and random
effects models were used,17 taking the sample size of the cohorts
and the possibility of statistical heterogeneity among the studies
into account. The latter was examined with Cochrane’s Q test
and the I2 statistic. In sensitivity analyses, the nested case-control
studies and, separately, death in the first three years of follow
up were excluded from the meta-analyses, but this did not
change the overall findings and these results are therefore not
shown. Dose-response relationships were assessed by estimation
of a trend underlying the summary effect estimates of the
25(OH)D quintiles applying the best fitting equation of the form
y=m x b (y, effect estimate; m, constant1, x=number of quintile
(that is, 1, 2, 3, 4, or 5), b=constant2).
Subgroups to be analysed were chosen a priori with the aim to
stratify for the important non-modifiable risk factors for vitamin
D deficiency: sex, age, and season of blood draw.8 18 19
Cohort-specific subgroup analysis results were pooled in
meta-analyses, and in a sensitivity analysis the pooling of results
was restricted to those cohorts that could contribute data to all
subgroup analyses (ESTHER, Tromsø and NHANES III). In a
further sensitivity analysis, analyses were stratified by smoking
status (current; yes or no) to examine whether excluding current
smokers from the Tromsø study could have affected the results
of the overall meta-analysis.
All statistical tests were two sided using an α level of 0.05. The
meta-analyses were conducted with the statistical software
Comprehensive Meta-Analysis 2.0 (Biostat, Englewood NJ,
USA), the dose-response trend was assessed with Microsoft
Excel 2010 (Redmond, Washington, USA), and all other
analyses were conducted with SAS, version 9.2 (Cary, North
Carolina, USA). The competing risks analysis was carried out
with a SAS macro provided by G Heinze, Medical University
of Vienna, Austria.20
Results
The baseline characteristics of the analytical samples from
participating cohorts and the nested case-control studies are
shown in supplementary tables 3 and 4, respectively. All cohorts
included men and women and all age groups (50-79 years), with
exception of the SENECA study, which only recruited in the
age range 70-79 years. The median 25(OH)D concentrations
by cohort varied between 24 and 62 nmol/L. Lower values in
the Tromsø, MONICA/KORA, SENECA, and HAPIEE cohort
studies can in part be explained by there being few or no serum
samples being collected in summer or autumn. Interestingly,
the medians of 25(OH)D concentrations in the nested
case-control studies were consistently lower among cases than
controls (supplementary table 4).
Table 2⇓ shows 25(OH)D concentrations by baseline
characteristics of the study participants (HAPIEE cohorts are
again shown separately for cases and controls). There was no
clear trend in 25(OH)D by age, but the median 25(OH)D
concentrations were consistently lower among women than
men. As expected, there was a clear pattern of 25(OH)D
concentrations measured in winter or spring being substantially
lower than those measured in summer or autumn. In addition,
the median 25(OH)D concentrations were, with few exceptions
among the cases and controls of the HAPIEE cohorts, increasing
with categories of education, lowest in obese individuals, lowest
in current smokers, and higher among subjects who undertook
vigorous physical activity. There were no systematic differences
in 25(OH)D concentrations between subjects with and without
history of chronic diseases (diabetes, hypertension,
cardiovascular disease, or cancer).
Themedian follow-up time in individual cohorts varied between
4.2 and 15.8 years, during which 6695 study participants died,
including 2624 deaths from cardiovascular diseases and 2227
deaths from cancer (table 1⇓). Compared with models adjusted
for age, sex, and season (model 1), the risk ratios by 25(OH)D
quintile (using the top quintile as reference) were attenuated for
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all outcomes by additional adjustment for conventional risk
factors for premature mortality (model 2; supplementary tables
5-7). Further addition of common chronic diseases to the model
(model 3) did not lead to further material attenuations of the
risk ratios.
The forest plots of the meta-analyses of main results (model 2),
comparing the bottom and the top 25(OH)D quintile are shown
for all-cause mortality in fig 1⇓ and for cardiovascular and
cancer mortality in fig 2⇓. A low degree of heterogeneity of
effects in the individual cohort studies can be seen from the
forest plots. The horizontal bars (the confidence intervals)
overlap, and the boxes (the effect estimates) are mostly close
together. The pooled effect estimate in the meta-analysis for
all-cause mortality revealed a 1.6-fold higher mortality in the
bottom quintile compared with the top quintile (risk ratio 1.57
(95% confidence interval 1.36 to 1.81), fig 1⇓). Furthermore,
the association with cardiovascular mortality in subjects without
a history of cardiovascular disease (risk ratio 1.41 (1.18 to 1.68))
and in subjects with a history of cardiovascular disease (risk
ratio 1.65 (1.22 to 2.22)) and the association with cancer
mortality in subjects with a history of cancer (1.70 (1.00 to
2.88)) were of similar strength and all statistically significant
(fig 2⇓; detailed results shown in supplementary tables 6-9).
The only exception was cancer mortality in subjects without a
history of cancer, for whom there was no association (risk ratio
1.03 (0.89 to 1.20)).
The dose-response trends across all 25(OH)D quintiles show
curvilinear inverse associations for all-cause mortality and
cardiovascular mortality, and for cancer mortality in subjects
with a history of cancer (fig 3⇓; detailed results shown in
supplementary tables 5-9). For all-cause mortality, the risk ratio
for bottom versus top 25(OH)D quintile was almost unchanged
if subjects with a history of cardiovascular disease or of cancer
were excluded (supplementary table 10-11).
In analyses stratified for sex, age, and season, the association
of the bottom quintile of 25(OH)D concentration with the
outcomes did not differ substantially in the subgroups (pooled
results are shown in fig 4⇓, detailed results are shown in
supplementary tables 12-20). Restricting the analyses to cohorts
that can contribute to all subgroups produced similar results
(not shown), as did stratification by smoking status or exclusion
of events in the first three years of follow-up (not shown).
Heterogeneity statistics for the meta-analyses usually indicated
a low, statistically non-significant level of heterogeneity. When
statistically significant, heterogeneity could be attenuated to
non-significant levels by removal of one outlier study
(supplementary tables 5-20). In the numerous meta-analyses,
six out of the eight studies were identified as the outlier between
one and three times, which shows that being the outlier was
rather randomly distributed among the studies and did not
indicate incomparability of the study’s results.
Discussion
Principal findings
In this meta-analysis of eight prospective cohort studies from
Europe and the United States, the lowest quintile of serum
25(OH)D concentration was associated with increased all-cause
and cardiovascular mortality, with a curvilinear association
between 25(OH)D concentration and these outcomes. An
association with cancer mortality was only observed if subjects
had a history of cancer. Results were consistent across study
populations, sexes, age groups, and seasons of blood draw.
Comparison with other studies
This is the first meta-analysis of individual participant data on
the relationship of 25(OH)D and mortality. Previous
meta-analyses of published study results faced problems with
hardly comparable vitamin D categories (including tertiles,
quartiles, quintiles, or clinically defined categories).
Nevertheless, the pooled effect estimates from this meta-analysis
for all-cause mortality (risk ratio 1.57 (95% confidence interval
1.36 to 1.81)) and cardiovascular mortality (1.41 (1.18 to 1.68)
in subjects without cardiovascular disease at baseline) comparing
the lowest and highest quintile of 25(OH)D concentration agreed
with the meta-analyses of Zittermann et al21 for all-cause
mortality (risk ratio 1.41 (1.04 to 1.90)) and of Wang et al22 for
cardiovascular mortality (1.42 (1.19 to 1.71)). The most recent
meta-analysis, by Chowdhury et al,23 that recalculated published
effect estimates to derive comparisons of the bottom versus the
top tertile of vitamin D levels came to similar effect estimates
for all-cause mortality (relative risk 1.35 (1.22 to 1.49)) and
cardiovascular mortality (1.35 (1.13 to 1.61)). None of the
studies included in the reviews was conducted in eastern
European populations, which differ from western European
populations with respect to lifestyle (such as alcohol
consumption and nutrition) and socioeconomic characteristics.24
Our meta-analysis shows that the associations of low 25(OH)D
concentrations with all-cause and cardiovascular mortality
outcomes are as strong in eastern Europe as in western Europe,
northern Europe, or the US.
With respect to cancer mortality, the recent meta-analyses of
Chowdhury et al23 and Yin et al25 showed weak, albeit
statistically significant, elevated pooled risk ratios (1.14 (1.01
to 1.29) and 1.20 (1.02 to 1.43), respectively, after change of
reference category to highest 25(OH)D category in the
meta-analysis of Yin et al). Our meta-analysis revealed a clear
difference in the association of 25(OH)D and cancer mortality
between subjects with a history of cancer (risk ratio 1.70 (1.00
to 2.88)) and those without (1.03 (0.89 to 1.20)). This difference
might explain why the pooled effect estimates of the previous
meta-analyses were weak and why a large degree of
heterogeneity was seen among the included studies. Moreover,
it speaks for an important role of vitamin D in cancer prognosis
(as recently shown by others for colorectal and breast cancer
prognosis26). However, we cannot exclude reverse causality,
that is, that the cancer might have led to low 25(OH)D levels.
Furthermore, our study with the endpoint cancer mortality
cannot make assumptions about a potential role of vitamin D
in early phases of the carcinogenic process. A recent systematic
umbrella review of meta-analyses of observational studies
assessing the association of 25(OH)D levels with site-specific
cancer incidences concluded that there is evidence for an
association of 25(OH)D levels with colorectal cancer whereas
there is inconclusive or no evidence for an association of
25(OH)D with other cancer sites.27
The median 25(OH)D concentrations varied strongly between
northern, central and eastern Europe and the US in the same
seasons of blood collection. However, it is uncertain howmuch
of these differences are related to different ultraviolet B
exposure, vitamin D consumption in the diet, and vitamin D
fortification habits in the countries or are just artefacts of the
different 25(OH)D assays employed. The distributions of various
covariates were similar across the studies in this meta-analysis,
but differences in the season of sample collection could have
led to some of the observed differences. Importantly, the
25(OH)D assays used in the eight cohort studies were not
standardised to a common standard, and large differences in
concentrations may simply be due to different assay standards
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and materials.28 29However, a previous analysis of the SENECA
study that used a common 25(OH)D assay for analysis in 12
European countries was in agreement with our finding that
population means of 25(OH)D concentrations are higher in
northern than in southern Europe (differences of ≥20 nmol/L
were reported).2 The authors of the SENECA study mainly
suspected country differences in vitamin D fortification of foods,
such as margarine, as possible causes of the large regional
differences.30 This could also explain the higher 25(OH)D levels
in the US, where fortification of milk is the rule whereas it is
the exception in Europe.31
In addition, this analysis in eight population based studies
confirmed the observation of previous studies that 25(OH)D
concentrations vary strongly by age, sex, season, education,
obesity, physical activity, and smoking.8 18 19 Nevertheless, in
our meta-analyses of mortality endpoints, the results were
comparable despite cut-off values set at the quintiles varying
by cohort (and therefore country), or by other factors such as
age, sex, and season. Overall, this finding may support the view
that low 25(OH)D concentrations might be a marker for a poor
health status rather than a cause of premature mortality. The
direction from a poor health state to vitamin D deficiency seems
plausible because subjects with poor health typically spend less
time outdoors because of reduced capacity for physical activity,
limiting their production of provitamin D3 in the skin under
solar ultraviolet B radiation.32
Implications for vitamin D supplementation
recommendations
The question of causality could be best answered by randomised
controlled trials. Two recent systematic reviews of such trials
confirmed that vitamin D supply has an effect on mortality.23 33
However, the effects were weaker than suggested by
observational studies, and vitamin D supplementation seemed
to be effective only for the administration of vitamin D3 in
subjects with low 25(OH)D levels at baseline.23 33Mortality was
only a secondary outcome in most of the trials, initially designed
to study the effects of vitamin D and calcium supplementation
on osteoporotic outcomes. New trials with a focus on
non-skeletal outcomes are needed. Four large trials have started
in 2012 and are described elsewhere.34Among these, the VIDAL
study, which is currently undertaking a feasibility study, will
be particularly informative with respect to mortality outcomes
because it will be specifically designed to assess these endpoints
in older adults (65-84 year old citizens of Great Britain). First
results of this trial are expected between 2017 and 2020. Until
then, it seems reasonable to follow the US Institute ofMedicine
recommendations that evidence is not yet sufficient to
recommend vitamin D3 supplementation for subjects with
vitamin D insufficiency (defined as 30-50 nmol/L 25(OH)D)
but that subjects with vitamin D deficiency (<30 nmol/L
25(OH)D) could profit from vitamin D3 supplementation by
maintaining bone health and reduction of fracture risk.35
However, there is no consensus on the ideal cut-off values for
vitamin D deficiency, because they are currently based on the
prevention of osteoporotic outcomes, and other outcomes might
also be relevant.8 15 In our view, all-cause mortality is an
outcome with particularly high public health relevance and
should therefore be given high priority. A recent analysis of the
ESTHER cohort showed that the Institute of Medicine cut-offs
for vitamin D deficiency and insufficiency are not only
appropriate for osteoporotic outcomes but also for mortality
prediction.8 The former ESTHER analysis had been adjusted
for the main determinants of 25(OH)D levels and therefore
corrected for variations in 25(OH)D levels according to season
and sex. In this analysis, widely varying cut-off points specific
for country, sex, and season produced similar results, which
raises the question whether country, sex, and season might be
considered for defining vitamin D deficiency. Future population
based cohort studies with adequately standardised 25(OH)D
measurements are essential to obtain sex- and season-specific
cut-points for vitamin D deficiency. Caution should be used in
generalising existing cut-offs to other regions with different
latitudes.
Limitations and strengths
This meta-analysis of individual participant data has several
strengths: the variety of cohorts from all over Europe and the
US, the overall large size enabling subgroup analyses, almost
complete registry-based follow-ups, and the common statistical
analysis strategy. We did not use repeated 25(OH)D
measurements during follow-up because this would not have
had a strong influence on the results. Previous analyses of the
Tromsø and ESTHER study showed that 25(OH)D
concentrations are fairly stable even up to 14 years.8 36 The main
limitation of this meta-analysis of prospective cohort studies is
its observational nature. Despite adjustment for known potential
confounders, we cannot rule out the possibility that the observed
associations are confounded by other unmeasured factors, such
as impairments of the immune system.32 In addition, residual
confounding by variables that could have been measured with
a higher degree of detail (such as physical activity) is possible
but not a likely explanation for the observed strong associations
between 25(OH)D concentrations and mortality outcomes.
Conclusion
In this meta-analysis of eight prospective cohort studies, the
lowest 25(OH)D quintile was associated with increased all-cause
mortality, cardiovascular mortality, and cancer mortality (in
subjects with a history of cancer). The inverse association across
quintiles was curvilinear, and the effects were remarkably
consistent across countries, sexes, seasons of blood draw, and
age groups despite 25(OH)D cut-off values varying according
to these characteristics. To identify cut-off values for vitamin
D deficiency, 25(OH)D variation by geographic region, sex,
and season might need to be taken into account.
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What is already known on this subject
Mean serum 25-hydroxyvitamin D (25(OH)D) concentrations vary by country, sex, age, and season of blood draw
Vitamin D deficiency has been linked to all-cause and cardiovascular mortality, whereas results on cancer mortality have been inconsistent
What this study adds
In this large consortium of eight cohort studies from Europe and the United States, the bottom 25(OH)D quintile was associated with
increased all-cause and cardiovascular mortality and with cancer mortality in subjects with a history of cancer but not in subjects without
a history of cancer. These relationships were compellingly consistent across countries, sexes, age groups, and seasons of blood draw,
although cut-off values for the 25(OH)D quintiles varied among the analyses
In clinical practice, cut-off values for vitamin D deficiency might need to be made region-, sex-, and season-specific to identify those in
the population with the relatively lowest 25(OH)D concentrations
Vitamin D may play an important role in cancer prognosis
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Tables
Table 1| Description of cohort studies included in meta-analyses of the associations between serum 25-hydroxyvitamin D concentrations
and mortality outcomes
Mortality follow-upStudy population aged 50-79 years
Sampling
25(OH)D
assay*
Place and
years of
recruitmentStudy name
Cancer
deaths
CVD
deaths
Total
deaths
Mean
(SD)
follow-up
(years)
End of
follow-upRegistry
Age
range
Included in
analysis†
With
measured
25(OH)DTotal
5314201 33811.0 (2.2)2012State
wide
50-749 0839 5639 949Total cohortMen:
IDS-iSYS;
women:
Diasorin.
Both
standardised
to LC-MS/MS
Federal state
Saarland,
south west
Germany,
2000-02
ESTHER
4134981 14114.2 (3.6)2010Country
wide
50-794 406‡
non-smokers
6 57110 262Total cohortModular
E170 Roche
Town
Tromsø,
north Norway,
1994-95
(Tromsø 4)
Tromsø
6616536615.9 (5.7)2009Region
wide
50-749399626 316Random
subsample§
IDS-iSYSTown
Augsburg and
district, south
Germany,
1984-85,
1989-90,
1994-95
MONICA/KORA
51942708.3 (2.9)1998Region
wide
70-75661**8232 586Random
subsample¶
Competitive
protein
binding
assay
19 towns in
12 European
countries,
1988-89
SENECA
2081654537.9 (1.5)2011Country
wide
50-732 0292 2807 099Nested
case-control††
DIAsource
ELISA
6 towns in
Czech
Republic,
2002-05
HAPIEE Czech
Republic
1941334117.0 (1.2)2011Region
wide
50-711 7001 8798 121Nested
case-control††
DIAsource
ELISA
Town
Krakow,
Poland,
2002-05
HAPIEE Poland
1521463684.2 (1.2)2011Region
wide
50-741 5741 6916 339Nested
case-control††
DIAsource
ELISA
Town
Kaunas,
Lithuania,
2006-08
HAPIEE
Lithuania
6121 0032 34812.3 (4.5)2006Country
wide
50-795 6265 7406 822Total cohortDiasorin RIAUSA
1988-94
NHANES III
2 2272 6246 695———50-7926 01829 50957 376———Total
25(OH)D=25-hydroxyvitamin D; CVD=cardiovascular disease; ESTHER=Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie
chronischer Erkrankungen in der älteren Bevölkerung [German]; HAPIEE=Health, Alcohol and Psychosocial factors In Eastern Europe; LC-MS/MS=liquid chromatography
coupled with tandem mass spectrometry; MONICA/KORA=Monitoring of trends and determinants in cardiovascular disease—Cooperative Health Research in the
Region of Augsburg; NHANES=National Health and Nutrition Examination Survey; SENECA=Survey in Europe on Nutrition and the Elderly: a Concerted Action.
*Manufacturers of 25(OH)D assays: IDS-iSYS (Immunodiagnostic Systems, Frankfurt Main, Germany); Diasorin-Liaison (Diasorin, Stillwater, USA); DIAsource ELISA
(DIAsource ImmunoAssays, Louvain-La-Neuve, Belgium); Modular E170 Roche (Roche Diagnostics, Rotkreuz, Swizerland) and competitive protein-binding assay (not
commercially available).
†Numbers are lower than numbers with measured 25(OH)D due to missing covariates.
‡2 012 smokers were excluded from the Tromsø study because of concerns regarding the validity of the Roche 25(OH)D assay in smokers.
§Randomly selected stratified survey, sex and 10 year age groups.
¶25(OH)D concentrations were measured in random samples stratified by age and sex in those 16 of the 19 towns with blood collected during January and March 1989.
**Further two towns with 73 participants with measured 25(OH)D were excluded from this analysis because these towns did not participate in the mortality follow-up,
leaving the following 14 towns from 12 European countries for inclusion in this analysis. North Europe (Latitude >50° north): Elverum, Norway; Roskilde, Denmark;
Culemborg, Netherlands; Hamme, Belgium; central Europe (Latitude 45-59° north): Haguenau, France; Monor, Hungary; Burgdorf, Switzerland; Bellinzona, Switzerland;
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Table 1 (continued)
Mortality follow-upStudy population aged 50-79 years
Sampling
25(OH)D
assay*
Place and
years of
recruitmentStudy name
Cancer
deaths
CVD
deaths
Total
deaths
Mean
(SD)
follow-up
(years)
End of
follow-upRegistry
Age
range
Included in
analysis†
With
measured
25(OH)DTotal
Yverdon, Switzerland; Romans, France; south Europe (Latitude <45° north): Betanzos, Spain; Fara Sabina, Magliano Sabina, Poggio Mirteto, Italy; Vila Franca de Xira,
Portugal; Anogia, Archanes, Greece.
††25(OH)D was measured in cases (any death or non-fatal cardiovascular disease (CVD) event during follow-up) and controls frequency matched by sex and 5 year
age groups. For this analysis on mortality, subjects with non-fatal CVD during follow-up were excluded from the cases in a first step. In order to add a representative
sample of subjects with non-fatal CVD events to the controls, in a second step, the observed proportion of non-fatal CVD events in each age and sex specific stratum
in the total cohort was calculated. In a third step, these proportions were multiplied by the sample sizes in each stratum in the controls with measured 25(OH)D. In a
fourth step, the resulting numbers were randomly selected in each stratum from the group of subjects with non-fatal CVD during follow-up and added to the controls.
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Table 2| 25-hydroxyvitamin D concentrations by baseline characteristics of the study populations
Median (interquartile range) concentration of 25(OH)D (nmol/L)*
Characteristic
HAPIEE LithuaniaHAPIEE PolandHAPIEE Czech Rep
NHANES‡SENECA†MONICA-KORATromsøESTHER CasesControlsCasesControlsCasesControls
Age (years):
40
(30-56)
46
(37-58)
34
(24-43)
38
(29-48)
21
(14-30)
26
(18-39)
60 (44-80)*NA40 (29-54)56
(46-67)*
47
(35-63)*
50-59
41
(30-53)
46
(37-59)
36
(26-49)
39
(30-51)
24
(16-36)
31
(21-43)
61 (45-80)*NA42 (31-56)53
(42-64)*
46
(35-62)*
60-69
45
(33-56)
46
(37-59)
43
(28-76)
41
(34-49)
34
(21-56)
29
(20-45)
64 (48-82)*33 (23-47)36 (27-50)51
(41-63)*
43
(33-57)*
70-79
Sex:
38
(29-49)*
44
(35-56)*
32
(23-40)*
37
(28-47)*
20
(14-29)*
26
(18-38)*
57 (42-76)*31 (21-44)*37 (29-49)*52
(42-64)*
43
(33-54)*
Women
44
(32-57)*
47
(37-60)*
37
(27-50)*
40
(31-51)*
26
(17-38)*
31
(21-44)*
67 (50-85)*35 (26-49)*44 (31-60)*56
(46-66)*
52
(37-71)*
Men
Season§:
40
(30-55)
41
(35-51)*
35
(25-47)
38
(29-49)
24
(16-35)*
28
(19-40)*
58 (43-77)*32 (22-45)*36 (27-52)*51
(41-63)*
40
(31-54)*
Winter
38
(29-50)
44
(35-56)*
35
(26-47)
39
(30-50)
21
(14-30)*
28
(18-40)*
58 (43-76)*37 (27-53)*37 (27-49)*57
(46-68)*
40
(32-52)*
Spring
45
(31-51)
48
(40-58)*
NANANANA67 (49-84)*NA49 (36-61)*64
(53-75)*
53
(41-70)*
Summer
45
(34-58)
51
(40-64)*
35
(23-49)
43
(33-54)
28
(19-43)*
35
(24-45)*
65 (48-85)*NA48 (38-65)*51
(42-63)*
50
(37-67)*
Autumn
Education¶:
45
(34-55)
46
(38-56)
32
(25-43)
36
(28-46)*
20
(13-32)*
25
(16-38)*
60 (45-79)*32 (23-47)*35 (27-46)*52
(41-63)*
45
(34-61)*
Low
39
(29-50)
45
(37-57)
37
(25-48)
39
(30-50)*
24
(16-35)*
29
(20-41)*
62 (46-81)*36 (26-50)*42 (31-57)*55
(45-67)*
47
(35-64)*
Medium
44
(31-56)
47
(37-60)
35
(26-46)
39
(30-53)*
29
(21-38)*
34
(21-45)*
65 (47-84)*40 (29-56)*46 (33-64)*57
(46-68)*
49
(35-67)*
High
BMI**:
36
(26-56)
46
(36-58)
31
(22-42)
39
(29-52)*
23
(17-40)
30
(18-44)*
65 (47-86)*32 (22-51)*41 (30-57)56
(45-67)*
47
(35-63)*
Normal or
underweight
44
(31-54)
48
(38-61)
37
(28-49)
40
(32-51)*
24
(15-39)
31
(21-43)*
63 (47-82)*35 (26-48)*41 (31-55)54
(44-65)*
47
(35-64)*
Overweight
42
(33-51)
45
(36-56)
36
(26-46)
37
(29-46)*
25
(15-33)
28
(18-39)*
57 (42-74)*30 (22-43)*38 (27-53)49
(39-60)*
42
(33-57)*
Obesity
Smoking:
43
(31-52)*
46
(37-59)*
34
(26-44)*
40
(31-52)*
25
(14-39)*
30
(21-42)*
61 (46-79)*32 (22-46)*39 (29-53)*52
(42-64)*
44
(34-59)*
Never
46
(35-57)*
48
(38-61)*
39
(30-50)*
39
(30-50)*
27
(17-38)*
31
(20-43)*
66 (49-85)*38 (28-52)*48 (34-61)*55
(44-66)*
50
(37-68)*
Former
35
(26-49)*
43
(33-54)*
32
(22-45)*
37
(29-46)*
20
(15-29)*
26
(18-38)*
56 (41-78)*31 (22-46)*37 (26-51)*Excluded41
(31-58)*
Current
Vigorous
physical activity:
39
(30-51)*
45
(35-58)*
35
(26-43)
36
(28-45)*
22
(14-33)
28
(18-40)*
58 (43-77)*32 (23-46)*37 (28-51)*52
(42-64)*
44
(33-58)*
No
45
(32-57)*
47
(37-59)*
35
(25-49)
40
(31-51)*
25
(16-38)
30
(20-42)*
67 (50-86)*44 (34-53)*48 (35-64)*57
(46-68)*
49
(36-66)*
Yes
History of
diabetes:
44
(31-55)*
46
(37-59)*
35
(25-47)
39
(30-50)
25
(17-36)*
30
(20-42)
64 (47-83)*32 (23-46)41 (30-55)54
(43-65)*
46
(35-62)*
No
38
(29-43)*
40
(33-50)*
37
(27-47)
39
(29-48)
19
(12-33)*
29
(18-39)
55 (41-72)*33 (25-42)40 (30-52)51
(42-60)*
44
(32-59)*
Yes
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Table 2 (continued)
Median (interquartile range) concentration of 25(OH)D (nmol/L)*
Characteristic
HAPIEE LithuaniaHAPIEE PolandHAPIEE Czech Rep
NHANES‡SENECA†MONICA-KORATromsøESTHER CasesControlsCasesControlsCasesControls
History of
hypertension:
40
(30-56)
46
(36-59)
35
(25-49)
39
(30-49)
24
(16-35)
30
(19-43)
64 (47-83)*33 (23-47)42 (31-57)*52
(41-64)*
47
(35-63)*
No
42
(31-52)
46
(37-58)
35
(26-46)
39
(30-50)
24
(15-36)
29
(20-41)
60 (44-80)*32 (22-44)38 (28-53)*54
(44-66)*
44
(34-60)*
Yes
History of CVD:
42
(31-54)
45
(36-59)*
36
(26-49)
39
(30-50)
24
(16-36)
30
(20-42)
62 (46-81)32 (23-46)41 (29-55)54
(43-65)
46 (34-62)No
41
(29-50)
48
(40-61)*
33
(25-42)
37
(28-49)
23
(14-30)
29
(20-40)
60 (44-81)34 (22-46)41 (33-54)54
(44-67)
46 (34-64)Yes
History of
cancer:
42
(31-53)
46
(37-59)
35
(25-47)
39
(30-50)
24
(16-36)
30
(20-42)
61 (45-81)*32 (23-46)43 (32-57)54
(43-65)*
46 (34-62)No
43
(29-55)
45
(37-59)
34
(26-47)
39
(32-46)
21
(12-28)
32
(20-43)
65 (47-83)*34 (14-40)33 (23-57)52
(42-63)*
44 (33-60)Yes
25(OH)D=25-hydroxyvitamin D; BMI=body mass index; CVD=cardiovascular disease; NA=not applicable.
*Statistically significant (P<0.05) by Wilcoxon rank-sum test.
†Regional differences in SENECA: median (interquartile range) 25(OH)D concentration (nmol/L); north Europe 39 (28-49), central Europe 34 (26-50), south Europe
26 (18-34).
‡Regional differences in NHANES: median (interquartile range) 25(OH)D (nmol/L); northeast 61 (47-82), mid-west 66 (47-84), south 62 (45-82), west 58 (44-76).
Differences by race and ethnicity: non-Hispanic white 70 (54-89), non-Hispanic black 48 (37-65), Mexican-American 56 (44-75), other (mainly Asian) 58 (46-78).
§Winter=December-February; Spring=March-May; Summer=June-August; Autumn=September-November.
¶Definition of categories of education by highest level of full-time education or years of full-time educations: low (primary school or less or ≤9 years), medium (more
than primary school but less than college or university or 10-12 years), high (college or university or ≥13 years).
**Definition of categories of weight by World Health Organization BMI categories: normal or underweight (<25 kg/m²), overweight (25-<30); obesity (≥30).
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Figures
Fig 1 Risk ratios of all-cause mortality for bottom versus top quintiles of 25-hydroxyvitamin D concentration in eight cohorts
(meta-analysis of individual participant data)
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Fig 2 Risk ratios of cardiovascular mortality in subjects with and without a history of cardiovascular disease (top panel) and
of cancer mortality in subjects with and without a history of cancer (bottom panel) for bottom versus top quintiles of
25-hydroxyvitamin D concentration in eight cohorts (meta-analysis of individual participant data)
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Fig 3 Dose-response trend of pooled effect estimates for the comparison of 25-hydroxyvitamin D quintiles (top quintile as
reference) with respect to mortality outcomes
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Fig 4 Sex-, age-, and season-specific pooled effect estimates for bottom versus top quintiles of 25-hydroxyvitamin D
concentration with respect to all-cause mortality, cardiovascular mortality in subjects without a history of cardiovascular
disease (CVD), and cancer mortality in subjects without a history of cancer
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